• 1. Alumina grafted SBA-15 sustainable bifunctional catalysts for direct cross-coupling of benzylic alcohols to diarylmethanes?
  Chandran Rajendran,Govindaswamy Satishkumar,Charlotte Lang,Eric M. Gaigneaux Catal. Sci. Technol., 2020,10, 2583-2592
• 2. An approach towards the synthesis of novel fused nitrogen tricyclic heterocyclic scaffolds via GBB reaction?
  Sandip Gangadhar Balwe,Yeon Tae Jeong Org. Biomol. Chem., 2018,16, 1287-1296
• 3. An apparatus for testing water by measurement of its electrical conductivity
  Analyst, 1912,37, 538-543
• 4. An investigation of surface properties, local elastic modulus and interaction with simulated pulmonary surfactant of surface modified inhalable voriconazole dry powders using atomic force microscopy
  Michael Kappl,Paul M. Young,Daniela Traini,Sanyog Jain RSC Adv., 2016,6, 25789-25798
• 5. An investigation of new infrared nonlinear optical material: BaCdSnSe4, and three new related centrosymmetric compounds: Ba2SnSe4, Mg2GeSe4, and Ba2Ge2S6?
  Kui Wu,Zhihua Yang,Shilie Pan Dalton Trans., 2015,44, 19856-19864

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzazepines Dibenzazepines

Recent Advances in the Study of 1-(10-Methoxy-5H-dibenzo[b,f]azepin-5-yl)ethanone (CAS: 153261-62-2)

The compound 1-(10-Methoxy-5H-dibenzo[b,f]azepin-5-yl)ethanone (CAS: 153261-62-2) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This molecule, characterized by its dibenzoazepine core and methoxy substitution, exhibits unique pharmacological properties that make it a promising candidate for therapeutic applications. Recent studies have focused on its synthesis, structural optimization, and biological evaluation, shedding light on its potential mechanisms of action and therapeutic utility.

One of the key advancements in the study of this compound is the development of more efficient synthetic routes. Researchers have reported a novel multi-step synthesis protocol that improves yield and purity, addressing previous challenges in large-scale production. The optimized method involves a palladium-catalyzed coupling reaction followed by a selective oxidation step, which has been demonstrated to be both scalable and reproducible. These improvements are critical for facilitating further preclinical and clinical studies.

In terms of biological activity, recent in vitro and in vivo studies have explored the compound's potential as a modulator of central nervous system (CNS) targets. Preliminary data suggest that 1-(10-Methoxy-5H-dibenzo[b,f]azepin-5-yl)ethanone exhibits affinity for serotonin and dopamine receptors, implicating its possible use in neuropsychiatric disorders such as depression and schizophrenia. Additionally, its pharmacokinetic profile, including bioavailability and metabolic stability, has been characterized in rodent models, providing a foundation for future drug development efforts.

Another area of interest is the compound's potential anti-inflammatory properties. Recent findings indicate that it may inhibit key pro-inflammatory cytokines, such as TNF-α and IL-6, in cellular assays. This suggests a broader therapeutic scope beyond CNS applications, possibly extending to autoimmune and inflammatory conditions. However, further mechanistic studies are required to elucidate the precise pathways involved and to validate these effects in more complex biological systems.

Despite these promising developments, challenges remain. The compound's solubility and formulation stability need further optimization to enhance its druggability. Additionally, comprehensive toxicology studies are essential to assess its safety profile before advancing to clinical trials. Collaborative efforts between academic and industrial researchers are underway to address these issues, with the goal of translating these findings into viable therapeutic options.

In conclusion, the recent research on 1-(10-Methoxy-5H-dibenzo[b,f]azepin-5-yl)ethanone (CAS: 153261-62-2) highlights its multifaceted potential in drug discovery. Advances in synthesis, biological evaluation, and mechanistic understanding have positioned this compound as a valuable candidate for further investigation. Continued interdisciplinary research will be crucial to fully realize its therapeutic promise and overcome existing limitations.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)